Determinants of seropositivity among HPV-16/18 DNA positive young women

BMC Infectious Diseases

Research Article

Leen-Jan van Doorn¹  Wim Quint¹  Mark E Sherman²  Carolina Porras²  Mark Schiffman²  Sholom Wacholder²  Allan Hildesheim²  Christina Bennett²  Diane Solomon²  Sarah Coseo²  Mahboobeh Safaeian²  Catherine Bougelet³  Ana Cecilia Rodríguez⁴  Rolando Herrero⁴  Silvia Jiménez⁴  Paula González⁴  Martha Hutchinson⁵ 

[1] DDL Diagnostic Laboratory, Voorburg, The Netherlands;Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA;GlaxoSmithKline Biologicals, Rixensart, Belgium;Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Liberia, Costa Rica;Women and Infants' Hospital, Providence, Rhode Island, USA;

关键词: Viral Load;    Sexual Debut;    High Viral Load;    Hormonal Contraceptive;    Abnormal Cytology;   

DOI  :  10.1186/1471-2334-10-238

 received in 2010-06-02, accepted in 2010-08-11,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundNot all women infected with HPV-16/18 have detectable levels of HPV-16/18 antibodies, those who seroconvert develop low antibody levels, and seroconversion occurs typically several months post-infection. We evaluated determinants of seropositivity among 646 women infected with HPV-16 and/or HPV-18.MethodsData are from the enrollment visit of the NCI-sponsored Costa Rica HPV Vaccine Trial. Sera were tested for HPV-16/18 antibodies by ELISA; cervical specimens were tested for HPV DNA using HC2 and SPF10/LiPA25. Odds ratios (OR) and 95% confidence intervals (CI) were computed.ResultsAmong HPV-16/18 DNA positives, seropositivity was 63.0% and 57.5%, respectively. Among HPV-16 DNA positives, seropositivity increased with lifetime number of sexual partners (p-trend = 0.01). Women with abnormal cytology and/or high viral load had a 1.63-2.79-fold increase in the detection of antibodies compared to women with normal cytology/low viral load. Current users of oral contraceptives had a 1.88-fold (95%CI, 1.14-3.09) increased detection of antibodies and current users of injectables had a 3.38-fold (95%CI, 1.39-8.23) increased detection compared to never users. Among HPV-18 DNA positive women, seropositivity was associated with current oral contraceptive use (OR 2.47; 95%CI 1.08-5.65).ConclusionsFactors associated with sustained HPV exposure (abnormal cytology, elevated HPV viral load, increasing lifetime partners) were predictive of HPV-16 seropositivity. Hormonal contraceptive use was associated with seropositivity suggesting an effect of hormones on immune responses to HPV. Patterns were less consistent for HPV-18. Follow up of incident HPV infections to evaluate seroconversion and their determinants is needed.

【 授权许可】

CC BY   
© Porras et al; licensee BioMed Central Ltd. 2010